Depacon (AbbVie Inc.)


Welcome to the PulseAid listing for the Depacon drug offered from AbbVie Inc.. This Anti-epileptic Agent [EPC],Decreased Central Nervous System Disorganized Electrical Activity [PE],Mood Stabilizer [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: AbbVie Inc.
NON-PROPRIETARY NAME: Valproate Sodium
SUBSTANCE NAME: VALPROATE SODIUM
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Anti-epileptic Agent [EPC],Decreased Central Nervous System Disorganized Electrical Activity [PE],Mood Stabilizer [EPC]
ROUTE: INTRAVENOUS
DOSAGE FORM: INJECTION
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 1996-12-30
END MARKETING DATE: 2019-11-01


Depacon HUMAN PRESCRIPTION DRUG Details:

Item DescriptionDepacon from AbbVie Inc.
LABELER NAME: AbbVie Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 100(mg/mL)
START MARKETING DATE: 1996-12-30
END MARKETING DATE: 2019-11-01
PRODUCT ID: 0074-1564_6fd04f96-6b5e-4cd8-9313-63877dd11f51
PRODUCT NDC: 0074-1564
APPLICATION NUMBER: NDA020593

Other VALPROATE SODIUM Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
AbbVie Inc.Depacon
Fresenius Kabi USA, LLCValproate Sodium
West-Ward Pharmaceuticals CorpValproate Sodium